Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: EGF (serum)

Search for Biomarkers

Analyte:

EGF (serum)

Platform:

Matrix:

Human Serum

Status:

Experienced Running

Required Sample Volume:

100 µL/well

Sensitivity-LLOQ/ULOQ:

LLOQ: 14.7 pg/mL
ULOQ: 10,700 pg/mL

Biological or Clinical Significance:

Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein[2] with 53 amino acid residues and three intramolecular disulfide bonds. EGF was originally described independently as a secreted peptide found in the submaxillary glands of mice and in human urine. Initially, human EGF was known as urogastrone.

Epidermal growth factor can be found in urine, saliva, milk, and plasma. The production of epidermal growth factor has been found to be stimulated by testosterone. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface. This stimulates ligand-induced dimerization,[8] activating the intrinsic protein-tyrosine kinase activity of the receptor.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies